Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.34 |
| ▸ | HPGDS | O60760 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.32 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.30 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.30 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17810262 | 0.96 | HPGDS (0.33) | KDM4EALDH1A1HPGDHSD17B10APOBEC3G | |
| SCHEMBL7602015 | 0.75 | KDM4E (0.34) | KDM4EALDH1A1HPGDHSD17B10APOBEC3G | |
| SCHEMBL19862537 | 0.75 | NPC1 (0.40) | KDM4EALDH1A1HPGDHSD17B10APOBEC3G | |
| SCHEMBL6633132 | 0.73 | KDM4E (0.37) | KDM4EALDH1A1HPGDHSD17B10APOBEC3G | |
| SCHEMBL6633135 | 0.73 | NPC1 (0.42) | KDM4EALDH1A1HPGDHSD17B10APOBEC3G | |
| SCHEMBL9977195 | 0.73 | MAPK13 (0.52) | HPGDSNPC1RAB9ASCN10A | |
| SCHEMBL903826 | 0.73 | CHRNB2 (0.41) | SCN10A | |
| SCHEMBL15098648 | 0.73 | CHRNB2 (0.41) | SCN10A | |
| SCHEMBL10144846 | 0.72 | MAPK13 (0.51) | HPGDSNPC1RAB9ASCN10A | |
| SCHEMBL15159435 | 0.72 | HPGDS (0.36) | HPGDSSCN10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180186806-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2018-07-05 | — | — | US | disclosed |
| US-9868745-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2018-01-16 | — | — | US | disclosed |
| US-20170342085-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2017-11-30 | — | — | US | disclosed |
| US-9809600-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2017-11-07 | — | — | US | disclosed |
| US-9682989-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2017-06-20 | — | — | US | disclosed |
| US-20170145027-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2017-05-25 | — | — | US | disclosed |
| US-20170029408-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2017-02-02 | — | — | US | disclosed |
| US-9511056-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2016-12-06 | — | — | US | disclosed |
| US-20160115175-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2016-04-28 | — | — | US | disclosed |
| US-20160083394-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2016-03-24 | — | — | US | disclosed |
| US-8575118-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-8575135-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-20130177530-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130164260-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130156732-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130137877-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-05-30 | — | — | US | disclosed |
| US-20120264711-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-10-18 | — | — | US | disclosed |
| US-20120258078-A1 | ANTIVIRAL COMPOUNDS OF THREE LINKED ARYL MOIETIES TO TREAT DISEASES SUCH AS HEPATITIS C | SCHERING CORPORATION (US) | 2012-10-11 | — | — | US | disclosed |
| US-20120157404-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20110223134-A1 | FUSED TRICYCLIC SILYL COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME LLC | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170145027-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | KDM4E 3215/4885ALDH1A1 3925/4885HPGD 4010/4885 |
| US-20170029408-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | KDM4E 2496/4885ALDH1A1 3957/4885HPGD 3745/4885 |
| US-20130177530-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | KDM4E 3215/4885ALDH1A1 3925/4885HPGD 4010/4885 |
| US-20170342085-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | KDM4E 3215/4885ALDH1A1 3925/4885HPGD 4010/4885 |
| US-20130137877-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | KDM4E 2496/4885ALDH1A1 3957/4885HPGD 3745/4885 |
| US-20120264711-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | KDM4E 2496/4885ALDH1A1 3957/4885HPGD 3745/4885 |
| US-20180186806-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | KDM4E 3215/4885ALDH1A1 3925/4885HPGD 4010/4885 |
| US-20120157404-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | KDM4E 2496/4885ALDH1A1 3957/4885HPGD 3745/4885 |
| US-20120258078-A1 | ANTIVIRAL COMPOUNDS OF THREE LINKED ARYL MOIETIES TO TREAT DISEASES SUCH AS HEPATITIS C | HAVCR2, ZC3HAV1, EIF2AK2 | KDM4E 2021/4885ALDH1A1 299/4885HPGD 2932/4885 |
| US-20130156732-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | KDM4E 3215/4885ALDH1A1 3925/4885HPGD 4010/4885 |
| US-20110223134-A1 | FUSED TRICYCLIC SILYL COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | FOXM1, ZC3HAV1L, C1S | KDM4E 3580/4885ALDH1A1 743/4885HPGD 3310/4885 |
| US-20160083394-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | KDM4E 3215/4885ALDH1A1 3925/4885HPGD 4010/4885 |
| US-20130164260-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | KDM4E 3215/4885ALDH1A1 3925/4885HPGD 4010/4885 |
| US-20160115175-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | KDM4E 3215/4885ALDH1A1 3925/4885HPGD 4010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.